Patients with HFrEF, HFmrEF, and HFpEF
In this study 2,302 patients in the KorAHF registry had echocardiography both at baseline and 1 year after index admission. The patients were stratified according to HF types. BMI, body mass index; BNP, B-type natriuretic peptide; BUN, blood urea nitrogen; COPD, chronic obstructive pulmonary disease; DBP, diastolic blood pressure; HF, heart failure; HFiEF, heart failure with improved ejection fraction; HFmrEF, heart failure with mid-range ejection fraction;
HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; HR, heart rate; LAD, left atrial diameter;
LVEDD, left ventricular end diastolic dimension; LVEF, left ventricular ejection fraction; LVESD, left ventricular end systolic diameter; MRA, mineralocorticoid receptor antagonist; NT-proBNP, N-terminal proB-type natriuretic peptide; NYHA, New York Heart Association; RAS, reninangiotensin system; RVSP, right ventricular systolic pressure; SBP, systolic blood pressure
Figure S1 Clinical outcomes according to HF phenotypes
HFiEF, heart failure with improved ejection fraction; HFmrEF, heart failure with midrange ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction HFmrEF, heart failure with midrange ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; IABP, intraaortic balloon pump; ICD, intracardiac defibrillator; ICU, intensive care unit; LMWH, low molecular heparin;
HFrEF: HFiEF versus persistent HFrEF
PCI, percutaneous coronary intervention; PCPS, percutaneous cardiopulmonary support 
Effect of beta-blockers in patients with HFiEF
Because beta blockers appear to be effective in patients with HFiEF on long-term outcomes, we performed additional analyses.
The baseline characteristics according to beta-blocker use are summarized in Table   S6 . In brief, the patients who received beta-blockers were more likely to be men and have a higher incidence of de-novo HF but a lower incidence of valvular heart disease and atrial fibrillation, at the time of diagnosis of HFiEF. There was no difference in the blood pressure between the groups; however, the heart rate was lower in the patients who received betablockers. Regarding medical therapy, patients who received beta-blockers were administered renin-angiotensin system (RAS) inhibitors and mineralocorticoid antagonists (MRAs) more frequently also at the time of diagnosis of HFiEF. NYHA, New York Heart Association; RAS-inhibitor, renin-angiotensin system inhibitor Propensity-score matching and inverse-probability treatment weighted analyses
In crude population, patients with beta-blockers had better 4-year all-cause mortality from HFiEF diagnosis. To minimize the bias by indication, we performed propensity-score matching (PSM) and inverse-probability treatment weighted (IPTW) analyses as sensitivity analyses. A total of 460 patients were 1:1-matched based on their propensity score. The baseline characteristics of the cohort after matching were well balanced, except for medication. In both analyses, beta-blocker use was associated with reduced 4-year all-cause mortality from HFiEF diagnosis ( Figure S2 ).
Figure S2 Beta-blockers in HFiEF after adjustment
Following variables were included for: age, sex, body mass index, previous history of heart failure, hypertension, diabetes mellitus, ischemic heart disease, valvular heart disease, chronic obstructive pulmonary disease, cerebrovascular disease, atrial fibrillation, malignancy, and New York Heart Association functional class.
Clinical outcomes according to beta-blocker dose and administration duration
When the subjects were stratified according to the beta-blocker dose, patients who received either high-or low-dose beta-blockers at the time of diagnosis of HFiEF showed better 4-year mortality than those who did not (log-rank P=0.014 and log-rank P=0.004, respectively);
however, there was no difference between the patients who received low-and high-dose betablockers (log-rank P=0.846) ( Figure S3 ).
Because the status of beta-blocker prescription changed between discharge from the index hospitalization and the time of HFiEF diagnosis, we further categorized the patients into four groups according to beta-blocker use at discharge and at HFiEF diagnosis. In the Kaplan-Meier analysis, patients who were on beta-blockers at the time of HFiEF diagnosis had a similar prognosis, regardless of beta-blocker use or not at discharge from the index hospitalization (log-rank P=0.014). In the exploratory subgroup analysis, the effect of beta-blockers was consistent across all subgroups.
The squares with horizontal lines indicate the HRs and corresponding 95% CIs.
CI, confidence interval; CKD, chronic kidney disease; DM, diabetes mellitus; HF, heart failure; HFiEF, heart failure with improved ejection fraction; HR, hazard ratio; IHD, ischemic heart disease; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; RASi, renin-angiotensin system inhibitor
Clinical outcomes according to rhythm: sinus rhythm versus atrial fibrillation
We stratified the patients according to rhythm. In patients with sinus rhythm, patients with beta-blockers had better survival than those without beta-blockers. By contrast, in patients with atrial fibrillation there was no difference between those with and without beta-blockers ( Figure S5 ).
Figure S5
Beta blockers in HFiEF according to rhythm
VI. Stratification according to onset of heart failure
Regarding the onset of heart failure, 55% and 45% of the patients had de-novo and acutelydecompensated heart failure (ADHF), respectively. Overall, patients with de-novo onset had better outcomes than those with ADHF. Patients with HFiEF had better survival than those with persistent HFrEF in both de-novo HF and ADHF ( Figure S6 ).
Regarding drug efficacy, patients with beta-blocker had lower mortality than those without beta-blocker in de-novo HF. Similarly, patients with beta-blockers had better survival in ADHF with a marginal significance. The effect of RAS inhibitors and MRA appeared to be neutral in both de-novo and ADHF patients ( Figure S7 and Figure S8 ). 
